Hybrigenics starts phase II clinical trial of inecalcitol in chronic lymphocytic leukemia
Hybrigenics, a bio-pharmaceutical company listed on Alternext in Paris, with a focus on research and development of new treatments against proliferative diseases, today announces the start of a phase II clinical trial of oral inecalcitol in patients with chronic lymphocytic leukemia.
Antisoma has started a randomised, controlled, multi-territory, phase IIb trial of AS1411 in patients with acute myeloid leukaemia.